The phase 3 clinical trial of the diabetes drug exenatide did not achieve its main goal of showing improvement in motor symptoms

The results from the Exenatide-PD3 study, a phase 3 clinical trial testing the diabetes drug exenatide (Bydureon) for Parkinson’s disease, have been shared with participants. Unfortunately, the trial did not meet its main goal of improving motor symptoms. This means that there was no significant difference in the progression of symptoms between those who took the drug and those who took a placebo. The researchers are now analyzing why these results differ from earlier promising findings and exploring what can be learned for future studies. Two additional smaller studies are still in progress. One is looking at brain scans to see if exenatide helps protect dopamine-producing neurons, which are key to Parkinson's. The other study is using a smartphone app to track participants' daily movement, tremors, and walking speed, aiming to improve how symptoms are measured in future research. Exenatide is a type of drug used for Type 2 diabetes, and this trial, conducted in the UK with 194 participants over 96 weeks, tested whether it could slow the progression of Parkinson’s. Although the main trial didn’t show a clear benefit, the researchers are working to understand the results better.